1357266-05-7

Basic information

• Product Name: (+)-(S)-4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine
• Synonyms: (+)-(S)-4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine
• CAS NO: 1357266-05-7
• Molecular Weight: 194.209
• Mol File: 1357266-05-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (+)-(S)-4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-(S)-4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine(1357266-05-7)
• EPA Substance Registry System: (+)-(S)-4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine(1357266-05-7)

Safety Data

• Hazardous Substances Data: 1357266-05-7(Hazardous Substances Data)

Usage

Uses

RO 5263397 is a trace amine-associated receptor 1 agonist (TAAR1).

Upstream product

• 506-68-3 bromocyane 
• 1270477-85-4 rac-2-amino-2-(3-fluoro-2-methylphenyl)ethanol 
• 1043498-53-8 4-(3-fluoro-2-methylphenyl)-4,5-dihydrooxazol-2-ylamine 
• 1270316-45-4 amino-(3-fluoro-2-methylphenyl)acetic acid 
• 1357266-66-0 amino-(3-fluoro-2-methylphenyl)-acetonitrile 
• 147624-13-3 3-fluoro-2-methylbenzaldehyde 

Relevant articles and documents

OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF

The present disclosure is directed to oxazoline mono- and hetero-pseudodimer compounds, such as compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: These compounds are useful for treating pain. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt or solvate thereof

Pharmaceutical combination

The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist)